Abstract:OBJECTIVES/SPECIFIC AIMS: MicroRNAs (miRNA) affect transcription of a number of genes involved in the development and progression of diabetic nephropathy (DN), and have become attractive therapeutic targets and biomarkers. Elevated renal gluconeogenesis, fibrosis, and albuminuria are early markers of incipient DN. Recent studies report that renal miRNA-451 may protect against DN and reduce renal gluconeogenesis in rodent models. MiRNA-451 is thought to act by targeting select factors resulting from disrupted insulin and growth factor signaling and the mechanistic-target of rapamycin (mTOR) in early DN. This study aimed to elucidate the role of miRNA-451 in the development and progression of DN. METHODS/STUDY POPULATION: To further elucidate the role of miRNA-451 in DN, we placed male insulin-resistant, TALLYHO/Jng mice on a high-fat diet (60% kCal). The mice were divided into 2 treatment groups and received 8 consecutive weekly intraperitoneal injections of locked nucleic acid (LNA) miR-451-inhibitor or LNA-scrambled compound (2 mg/kg·bw; n=8/treatment). Mice were euthanized after 12 weeks (4 weeks sans injections) and kidneys, liver, pancreas and abdominal adipose tissue were harvested for analysis. RESULTS/ANTICIPATED RESULTS: Renal homogenate expression of miRNA-451 was drastically reduced in inhibitor-treated mice (~6-fold) in comparison with scramble-treated mice. Western blotting of cortex homogenates for indicators of fibrosis and targets of miRNA-451 revealed a significant reduction in collagen IV (marker of epithelial integrity) in inhibitor-treated mice. In addition, metalloproteinase type 9 (MMP9, a known type IV collagenase), YWHAZ (a scaffolding protein and known target of miR-451), mTOR, and fructose bisphosphatase (FBP1, a rate-limiting gene in gluconeogenesis) were significantly increased in this group in comparison to scramble-treated mice. However, no differences were found in protein levels for glucose-6-phosphatase (G-6-Pase) or phosphoenolpyruvate (PEPCK), 2 additional gluconeogenic rate-limiting genes. MiRNA-451 antagonist did not significantly affect final body weight or blood glucose; however, mean blood sodium concentrations were slightly, but significantly higher (2%) in the LNA-inhibitor treated group (when compared with the scramble-treated group). No differences in blood potassium or chloride were found. Anion gap was 90% higher in the LNA-inhibitor treated group when compared with scramble-treated mice. No differences in urinary albumin to creatinine ratio were found between the two treatment groups. However, Masson Trichrome scoring revealed a 59% increase in fibrosis in inhibitor-treated mice. DISCUSSION/SIGNIFICANCE OF IMPACT: Collectively, these findings support a potentially protective role of miRNA-451 in attenuating signaling via mTOR that may alter both renal gluconeogenic potential (contributing to the diabetic phenotype) and activation and progression of renal fibrosis. Therapies to enhance miRNA-451 signaling may be beneficial to reduce renal pathology associated with DN.

An Endoplasmic Reticulum Stress-Regulated Lncrna Hosting a Microrna Megacluster Induces Early Features of Diabetic Nephropathy

A Novel Identified Circular RNA, mmu_mmu_circRNA_0000309, Involves in Germacrone-Mediated Improvement of Diabetic Nephropathy Through Regulating Ferroptosis by Targeting miR-188-3p/GPX4 Signaling Axis

Long Non-Coding RNA Lncmgc Mediates the Expression of TGF-β-induced Genes in Renal Cells Via Nucleosome Remodelers.

Long noncoding RNA lncMGC mediates the expression of TGF-β-induced genes in renal cells via nucleosome remodelers

Dysregulation of Lncrnas GM5524 and GM15645 Involved in High‑glucose‑induced Podocyte Apoptosis and Autophagy in Diabetic Nephropathy.

2466 MicroRNA-451: A potential key player in the development of diabetic nephropathy in an insulin resistant mouse model

Long Noncoding RNA NONHSAG053901 Promotes Diabetic Nephropathy Via Stimulating Egr‐1/TGF‐β‐mediated Renal Inflammation

Noncoding RNAs as therapeutic targets in early stage diabetic kidney disease

RNA-sequencing reveals genome-wide long non-coding RNAs profiling associated with early development of diabetic nephropathy

Microarray Analysis of Long Noncoding Rna Expression Patterns in Diabetic Nephropathy

MicroRNAs in diabetic nephropathy: functions, biomarkers, and therapeutic targets

LncRNA NEAT1 Promotes Extracellular Matrix Accumulation and Epithelial-to-mesenchymal Transition by Targeting Mir-27B-3p and ZEB1 in Diabetic Nephropathy

Long non‑coding RNA L13Rik promotes high glucose-induced mesangial cell hypertrophy and matrix protein expression by regulating miR-2861/CDKN1B axis

Role of MicroRNA 1207-5P and Its Host Gene, the Long Non-Coding RNA Pvt1, as Mediators of Extracellular Matrix Accumulation in the Kidney: Implications for Diabetic Nephropathy

Long non-coding RNA DLX6-AS1 is the key mediator of glomerular podocyte injury and albuminuria in diabetic nephropathy by targeting the miR-346/GSK-3β signaling pathway

LINC01232 targeting miR-1250-3p/MSH2 axis attenuates mesangial cell proliferation and fibrosis in diabetic nephropathy

Differential Expression and Therapeutic Efficacy of Microrna-346 in Diabetic Nephropathy Mice

Decreased DANCR Contributes to High Glucose‐induced Extracellular Matrix Accumulation in Human Renal Mesangial Cell Via Regulating the TGF‐β/Smad Signaling

LRNA9884, a Novel Smad3-Dependent Long Noncoding RNA, Promotes Diabetic Kidney Injury in Db/db Mice Via Enhancing MCP-1-Dependent Renal Inflammation.

Mir-98-5p Alleviated Epithelial-to-Mesenchymal Transition and Renal Fibrosis Via Targeting Hmga2 in Diabetic Nephropathy

MiRNA-133a-3p Attenuates Renal Tubular Epithelial Cell Injury via Targeting MALM1 and Suppressing the Notch Signaling Pathway in Diabetic Nephropathy